Prescription drugs; price transparency, definitions. (HB2007)

Introduced By

Del. Mark Sickles (D-Alexandria) with support from 12 copatrons, whose average partisan position is:

Those copatrons are Del. Hala Ayala (D-Woodbridge), Del. Buddy Fowler (R-Ashland), Del. Wendy Gooditis (D-Clarke), Del. Elizabeth Guzman (D-Dale City), Del. Mark Keam (D-Vienna), Del. Mark Levine (D-Alexandria), Del. Kathleen Murphy (D-McLean), Del. Cia Price (D-Newport News), Del. Suhas Subramanyam (D-Sterling), Del. Kathy Tran (D-Springfield), Del. Rodney Willett (D-Henrico), Sen. Scott Surovell (D-Mount Vernon)

Description

Prescription drug price transparency. Directs the Department of Health to enter into a contract or an agreement with a nonprofit data services organization to collect, compile, and make available on its website information about prescription drug pricing and requires every health carrier, pharmacy benefits manager, and drug manufacturer to report information about prescription drug prices to the nonprofit data services organization with which the Department of Health has entered into a contract for such purpose. The bill provides that in any case in which the Department determines that the data reported by health carriers, pharmacy benefit managers, and drug manufacturers is insufficient, the Department may require wholesale distributors to report certain data about prescription drug costs. The bill has a delayed effective date of January 1, 2022, and directs the Department of Health to adopt emergency regulations to implement the provisions of the bill. Read the Bill »

Status

04/17/2021: Awaiting a Vote in the Finance and Appropriations Committee

History

Post a Public Comment About this Bill